DYAI

Latest SEC Filings & News for DYAI

2 most recent filings and news items mentioning DYAI. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/DYAI/news?limit=20"

Pull DYAI filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

OtherJun 15, 2026Positive

Dyadic highlights accelerated interest in C1 biomanufacturing platform

Dyadic International reports growing interest in its C1 protein production platform for rapid vaccine and antibody manufacturing amid Ebola preparedness efforts. The platform can progress from viral gene sequence to purified antigen in approximately 15 days, positioning the compa

View filing at SEC.gov →

OtherMay 28, 2026Positive

Dyadic partners with Scripps Research on hantavirus antibody and vaccine development

Dyadic International announced a collaboration with Scripps Research to develop monoclonal antibody and vaccine candidates targeting hantaviruses using its C1 microbial platform. The partnership leverages prior infectious disease research and aims to accelerate biologic productio

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.